Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Add as a preferred source on Google
LAWRENCE, Mass., April 16, 2018 -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics for the potential treatment of diabetes and related complications, will hold a conference call on Wednesday, April 18, 2018 at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to discuss recent business developments, including its recent acquisition of CureDM and recently announced intention to acquire Medical Technology Associates II, Inc. Boston Therapeutics management will host the presentation, followed by a question and answer period.
Date: Wednesday, April 18, 2018
Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)
U.S. dial-in: 1-800-263-0877
TOLL/INTERNATIONAL dial-in: 1-323-794-2094
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact ViaVid at toll-free (888) 562-0262 | tel (604) 929-1352.
The conference call will be broadcast live and available for replay at the Investor Relations section of Boston Therapeutics website. A replay of the conference call will be available after 8:00 p.m. Eastern time on the same day through May 02, 2018.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 2971422
Investor Relations Contact: Loraine V. Upham
About Boston Therapeutics, Inc. www.bostonti.com
Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) and with an office in Albuquerque, NM is an innovator in design, development and commercialization of novel compounds to treat diabetes and diabetes related complications. The company has proprietary compounds based on glucose chemistry, peptide chemistry and protein conjugates.
Contact: Boston Therapeutics, Inc.
Loraine Upham, COO
Phone: 603-935-9799
Email: [email protected]
www.bostonti.com
